The ABRACL Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. In this model, the ABRACL gene has been disrupted to generate a loss-of-function tool, eliminating the need for clonal selection and enabling studies that encompass heterogeneous gene-editing outcomes across the population. These ready-to-use cells serve as an in vitro system for exploring ABRACL-dependent processes in actin cytoskeleton dynamics, cell motility, and proliferation within a colorectal cancer context.
HT29 cells are an adherent epithelial line originally isolated from a primary colon adenocarcinoma of a 44-year-old Caucasian female. They are a classic model in intestinal epithelial biology and colorectal cancer research, routinely employed in drug screening, differentiation studies, and oncogenic signaling analysis. The line retains key features of colorectal tumor cells, including robust growth and the ability to form polarized monolayers, making it well-suited for gene-edited models that probe migratory and proliferative phenotypes.
ABRACL functions as a regulator of the actin cytoskeleton, promoting cell migration and proliferation. It is activated downstream of integrin-mediated adhesion and growth factor receptors such as EGFR, and it acts upstream of the small GTPase RhoA and its effector kinase ROCK. Through interactions with WASF family proteins and the Arp2/3 complex, ABRACL stimulates actin polymerization, facilitating lamellipodial protrusion and focal adhesion dynamics. Consequently, ABRACL disruption is anticipated to impair actin reorganization, reducing cellular motility via altered Rho GTPase signaling and focal adhesion turnover.
In the HT29 colorectal adenocarcinoma setting, ABRACL knockout provides a physiologically relevant platform to dissect its contribution to malignant behaviors. Given that ABRACL is implicated in metastatic cancers, this polyclonal knockout population helps elucidate pathways driving colorectal tumor invasion and metastasis without the risk of clonal artifacts. The population-level readout may better mirror tumor heterogeneity and support the identification of ABRACL-dependent vulnerabilities.
This model is suited for detailed colorectal cancer metastasis studies, migration and invasion assays (Transwell and wound healing), proliferation analyses (MTT and BrdU incorporation), and immunofluorescence imaging of F-actin structures. It is also used in drug target validation and RhoA activation assays to examine downstream signaling events. For more information, please contact Ascent Research.
